In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies

Vaccine

Volumn 30, Issue 46, 2012, Pages 6578-6587

  Mohamed, Yehia S ^a,b   Dunnion, Debbie ^a   Teobald, Iryna ^a   Walewska, Renata ^a,c   Browning, Michael J ^a,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b AL AZHAR UNIVERSITY   (Egypt)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cancer; Fusion; Hybrid; Immunotherapy; Leukaemia; Lymphoma; Myeloma; Vaccine

Indexed keywords

B7 ANTIGEN; BLOCKING ANTIBODY; CD40 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL FUSION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DAUDI CELL; EX VIVO STUDY; FREEZE THAWING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYBRID CELL; HYBRIDOMA; IMMUNOSTIMULATION; IN VITRO STUDY; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE CULTURE; TUMOR CELL;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CELL FUSION; HEMATOLOGIC NEOPLASMS; HUMANS; HYBRID CELLS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 84867014478     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.032     Document Type: Article

References (31)

1. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of anti-tumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997, 3:558-561.
2. Wang J., Saffold S., Cao X., Krauss J., Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998, 161:5516-5524.
3. Tanaka Y., Koido S., Chen D., Gendler S.J., Kufe D., Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001, 101:192-200.
4. Chen D., Xia J., Tanaka Y., Chen H., Koido S., Wernet O., et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003, 109:300-307.
5. Siders W.M., Vergilis K.L., Johnson C., Shields J., Kaplan J.M. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 2003, 7:498-505.
6. Xia J., Tanaka Y., Koido S., Liu C., Mukherjee P., Gendler S.J., et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003, 170:1980-1986.
7. Wells J.W., Cowled C.J., Darling D., Guinn B.A., Farzaneh F., Noble A., et al. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunol Immunother 2007, 56:1861-1873.
8. Kugler A., Seseke F., Thelen P., Kallerhoff M., Muller G.A., Stuhler G., et al. Autologous and allogeneic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 1998, 82:487-493.
9. Trefzer U., Weingart G., Chen Y., Herberth G., Adrian K., Winter H., et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial for metastatic melanoma. Int J Cancer 2000, 85:618-626.
10. Krause S.W., Neumann C., Soruri A., Mayer S., Peters J.H., Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002, 25:421-428.
11. Marten A., Renoth S., Heinicke T., Albers A., Pauli A., Mey U., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003, 14:483-494.
12. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004, 10:4699-4708.
13. Trefzer U., Herberth G., Wohlan K., Milling A., Thiemann M., Sherev T., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 2004, 110:730-740.
14. Avigan D.E., Vasir B., George D.J., Oh W.K., Atkins M.B., McDermott D.F., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007, 30:749-761.
15. Edwards P.A.W., Smith C.M., Neville A.M., O'Hare M.J. A human-hybridoma system based on a fast growing mutant of the ARH-77 plasma cell leukaemia-derived line. Eur J Immunol 1982, 12:641-648.
16. Dunnion D.J., Cywinski A.L., Tucker V.C., Murray A.K., Rickinson A.B., Coulie P., et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999, 98:541-550.
17. Kerr B.M., Lear A.L., Rowe M., Croom-Carte D., Young L.S., Rookes S.M., et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992, 187:189-201.
18. Van Baren N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F., et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999, 94:1156-1164.
19. Greiner J., Ringhoffer M., Taniguchi M., Li L., Schmitt A., Shiko H., et al. mRNA expression of leukaemia-associate antigens in patients with acute myeloid leukaemia for the development of specific immunotherapies. Int J Cancer 2004, 108:704-711.
20. Schmidt S.M., Schag K., Muller M.R., Weck M.M., Appel S., Kanz L. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003, 102:571-576.
21. Hosken N.A., Bevan M.J. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 1990, 248:367-370.
22. Mohamed Y.S., Dunnion D., Teobald I., Walewska R., Browning M.J. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro. Immunobiology 2012, 217:719-729.
23. Galea-Lauri J., Darling D., Mufti G., Harrison P., Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukaemia-derived antigens: evaluation of dendritic cell-leukaemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002, 51:299-310.
24. Gong J., Koido S., Kato Y., Tanaka Y., Chen D., Jonas A., et al. Induction of anti-leukaemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 2004, 28:1303-1312.
25. Klammer M., Waterfall M., Samuel K., Turner M.L., Roddie P.H. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol 2005, 129:340-349.
26. Raje N., Hideshima T., Davies F.E., Chauhan D., Treon S.P., Young G., et al. Tumor cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004, 125:343-352.
27. Vasir B., Borges V., Wu Z., Grosman D., Rosenblatt J., Irie M., et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 2005, 129:687-700.
28. Rosenblatt J., Vasir B., Uhl L., Blotta S., Macnamara C., Somaiya P., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011, 117:393-402.
29. Fabre J.W. The allogeneic response and tumor immunity. Nat Med 2001, 7:649-652.
30. Yasuda T., Kamigaki T., Kawasaki K., Nakamura T., Yamamoto M., Kanemitsu K., et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon carcinoma. Cancer Immunol Immunother 2007, 56:1025-1036.
31. Suzuki T., Fukuhara T., Tanaka M., Nakamura A., Akiyama K., Sakakibara T., et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005, 11:58-66.